author-photo

Lotta Ohm

Karolinska University Hospital

22

Papers

813

Citations

Citation Trend

Filter By

Papers (18) Sort By

Journal Conference Others

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia

2017 Leukemia
Show All
- Source
- Cite
- Save
Citations (133)
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)

2015 European Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (49)
Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib.

2015 Leukemia & Lymphoma
Show All
- Source
- Cite
- Save
Citations (18)
Mature, Adaptive-like CD56(DIM) NK Cells in Chronic Myeloid Leukemia Patients in Treatment Free Remission

2015 Blood
Show All
- Source
- Cite
- Save
Citations (2)
Disease Relapse After Tyrosine Kinase Inhibitor Treatment Discontinuation in Chronic Myeloid Leukaemia is Related to Both Low Number and Impaired Function of NK Cells

2014 Scandinavian Journal of Immunology
Show All
- Source
- Cite
- Save
Citations (1)
Early Disease Relapse after Tyrosine Kinase Inhibitor Treatment Discontinuation in CML Is Related Both to Low Number and Impaired Function of NK-Cells

2014 Blood
Show All
- Source
- Cite
- Save
Citations (6)
Increased Risk of Cardiovascular Events Associated with TKI Treatment in Chronic Phase Chronic Myeloid Leukemia : Data from Swedish Population-Based Registries

2014 Blood
Show All
- Source
- Cite
- Save
Citations (9)
Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry

2013 Blood
Show All
- Source
- Cite
- Save
Citations (95)
Dasatinib Treatment Induces Fast and Deep Responses In Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients In Chronic Phase: Clinical Results From a Randomized Phase 2 Study (NordCML006)

2013 Blood
Show All
- Source
- Cite
- Save
Citations (3)
Early landmark analysis of imatinib treatment in CML chronic phase: less than 10% BCR-ABL by FISH at 3 months associated with improved long-term clinical outcome.

2012 American Journal of Hematology
Show All
- Source
- Cite
- Save
Citations (14)